GW Pharmaceuticals says the US Patent and Trademark Office has issued a ‘notice of allowance’ for a patent which protects delivery of the group’s Sativex product formulation. The subject patent specifically covers an improved method of sublingual delivery to a human consisting of administering an extract of cannabis in ethanol and propylene glycol.
Leave a Reply
You must be logged in to post a comment.